319 related articles for article (PubMed ID: 9476375)
1. [Mixed myelodysplastic and myeloproliferative syndromes].
Neuwirtová R; Mociková K; Jelínek J; Musilová J; Havlícek F; Adamkov M; Michalová K; Cermák J; Jonásová A; Smolíková A; Straub J; Tothová E; Voglová J; Vozobulová V; Waltrová L
Cas Lek Cesk; 1997 Dec; 136(23):724-9. PubMed ID: 9476375
[TBL] [Abstract][Full Text] [Related]
2. Mixed myelodysplastic and myeloproliferative syndromes.
Neuwirtová R; Mociková K; Musilová J; Jelínek J; Havlícek F; Michalová K; Adamkov M
Leuk Res; 1996 Sep; 20(9):717-26. PubMed ID: 8947580
[TBL] [Abstract][Full Text] [Related]
3. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders.
Del Cañizo MC; Brufau A; Mota A; Lopez N; Fernandez ME; Vallejo C; Hernandez JM; Garcia JL; San Miguel JF
Haematologica; 1998 Jan; 83(1):3-7. PubMed ID: 9580461
[TBL] [Abstract][Full Text] [Related]
4. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
5. Myelodysplastic syndromes: the pediatric point of view.
Locatelli F; Zecca M; Pession A; Maserati E; De Stefano P; Severi F
Haematologica; 1995; 80(3):268-79. PubMed ID: 7672722
[TBL] [Abstract][Full Text] [Related]
6. Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cortes J; Giles F; O'Brien S; Thomas D; Albitar M; Rios MB; Talpaz M; Garcia-Manero G; Faderl S; Letvak L; Salvado A; Kantarjian H
Cancer; 2003 Jun; 97(11):2760-6. PubMed ID: 12767088
[TBL] [Abstract][Full Text] [Related]
7. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
8. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
[TBL] [Abstract][Full Text] [Related]
9. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
10. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
11. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes.
Wulfert M; Küpper AC; Tapprich C; Bottomley SS; Bowen D; Germing U; Haas R; Gattermann N
Exp Hematol; 2008 May; 36(5):577-86. PubMed ID: 18439489
[TBL] [Abstract][Full Text] [Related]
12. [Clonogenic cells of acute leukemia secondary to myeloproliferative and myelodysplastic syndromes].
Almeida J; del Cañizo MC; Galende J; Vidriales B; Nieto MJ; Hernández MD; Rodríguez MJ; San Miguel JF
Sangre (Barc); 1994 Oct; 39(5):331-5. PubMed ID: 7754436
[TBL] [Abstract][Full Text] [Related]
13. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity.
Schmitt-Graeff A; Thiele J; Zuk I; Kvasnicka HM
Haematologica; 2002 Apr; 87(4):392-9. PubMed ID: 11940483
[TBL] [Abstract][Full Text] [Related]
14. [Clinical biological features of mixed myeloid diseases].
Gritsaev SV; Abldulkadyrov KM; Tiranova SA; Kapustin SI; Martynkevich IS; Bessmel'tsev SS; Rugal' VI; Bakaĭ MP
Ter Arkh; 2004; 76(12):68-73. PubMed ID: 15724931
[TBL] [Abstract][Full Text] [Related]
15. Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes.
Sakuma T; Hayashi Y; Kanomata N; Murayama T; Matsui T; Kajimoto K; Hanioka K; Chihara K; Maeda S
Pathol Int; 2006 Apr; 56(4):191-9. PubMed ID: 16634964
[TBL] [Abstract][Full Text] [Related]
16. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
Bock O
Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
[TBL] [Abstract][Full Text] [Related]
17. Splenectomy in patients with mixed myelodysplastic/myeloproliferative disease.
Kraemer D; Rüdiger T; Reimer P; Müller-Hermelink HK; Wilhelm M
Ann Hematol; 2002 Jun; 81(6):308-11. PubMed ID: 12107559
[TBL] [Abstract][Full Text] [Related]
18. Multiparameter flow cytometry reveals myelodysplasia-related aberrant antigen expression in myelodysplastic/myeloproliferative neoplasms.
Kern W; Bacher U; Schnittger S; Alpermann T; Haferlach C; Haferlach T
Cytometry B Clin Cytom; 2013 May; 84(3):194-7. PubMed ID: 23283847
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous intramedullary apoptosis is present in disorders other than myelodysplasia.
Irvine AE; Magill MK; Somerville LE; McMullin MF
Exp Hematol; 1998 May; 26(5):435-9. PubMed ID: 9590661
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?
Subirá D; Font P; Villalón L; Serrano C; Askari E; Góngora E; Castañón S; Gonzalo R; Mata R; Román A; Llamas P
Transl Res; 2008 May; 151(5):240-5. PubMed ID: 18433705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
